Physician profile
James P Daugherty
NPI 1598727083
$10,622.37
in general payments reported to CMS, 2019-2025
63 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $1,232 · 2021: $1,351 · 2022: $2,029 · 2023: $1,766 · 2024: $1,807 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,772 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,771.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,421.03 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,415.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $782.73 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Pfizer INC. | $651.03 | 2019-2024 | |
| Amgen INC. | $473.26 | 2019-2023 | Kyprolis |
| Incyte Corporation | $355.17 | 2020-2025 | Jakafi |
| Janssen Biotech, INC. | $352.61 | 2019-2025 | Darzalex, Rybrevant, Imbruvica |
| Daiichi Sankyo INC. | $337.65 | 2019-2024 | Enhertu |
| Exelixis INC. | $313.16 | 2019-2024 | Cabometyx |
| Lilly USA, LLC | $289.20 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $273.60 | 2019-2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.59 | 2019-2023 | Gilotrif |
| Eisai INC. | $246.37 | 2019-2023 | |
| Genentech USA, INC. | $216.55 | 2019-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Seagen INC. | $200.55 | 2021-2023 | Tukysa, Padcev |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.